Chris Shibutani
Stock Analyst at Goldman Sachs
(3.23)
# 1,010
Out of 4,876 analysts
99
Total ratings
51.92%
Success rate
1.29%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $32.58 | +206.94% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.31 | +129.01% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $8.96 | +67.41% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $28.81 | +11.07% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $106.72 | +28.37% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $9.03 | +265.65% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $284.27 | +6.24% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $35.87 | +42.18% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $152.41 | +1.70% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $6.33 | -36.81% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $9.86 | +102.84% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $775.45 | -6.76% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $20.61 | +26.15% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $125.42 | +21.99% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $182.31 | -5.11% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $25.76 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $46.35 | +48.87% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $19.96 | -34.87% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $36.91 | -37.69% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.34 | +2,036.75% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $44.12 | +17.86% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $24.19 | +148.04% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $6.93 | +159.74% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $5.01 | +239.32% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.38 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.69 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.33 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.64 | - | 3 | May 2, 2017 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $32.58
Upside: +206.94%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.31
Upside: +129.01%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $8.96
Upside: +67.41%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $28.81
Upside: +11.07%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $106.72
Upside: +28.37%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $9.03
Upside: +265.65%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $284.27
Upside: +6.24%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $35.87
Upside: +42.18%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $152.41
Upside: +1.70%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $6.33
Upside: -36.81%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $9.86
Upside: +102.84%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $775.45
Upside: -6.76%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $20.61
Upside: +26.15%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $125.42
Upside: +21.99%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $182.31
Upside: -5.11%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $25.76
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $46.35
Upside: +48.87%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $19.96
Upside: -34.87%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $36.91
Upside: -37.69%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $2.34
Upside: +2,036.75%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $44.12
Upside: +17.86%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $24.19
Upside: +148.04%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $6.93
Upside: +159.74%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $5.01
Upside: +239.32%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.38
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.69
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.33
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $29.64
Upside: -